- Ginsenoside Re
-
- $43.00 / 5mg
-
2026-02-02
- CAS:52286-59-6
- Min. Order:
- Purity: 99.78%
- Supply Ability: 10g
- Ginsenoside Re
-
- $1.00 / 1g
-
2025-02-13
- CAS:52286-59-6
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 1000
- Ginsenoside Re
-
- $0.00 / 20mg
-
2023-02-24
- CAS:52286-59-6
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Ginsenoside Re Basic information |
| | Ginsenoside Re Chemical Properties |
| Melting point | 201～203℃ | | Boiling point | 1011.8±65.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly), Pyridine (Slightly) | | pka | 12.85±0.70(Predicted) | | form | Solid | | color | White to Off-White | | Cosmetics Ingredients Functions | HUMECTANT
SKIN CONDITIONING
ANTIOXIDANT | | InChIKey | PWAOOJDMFUQOKB-WCZZMFLVSA-N | | LogP | 4.750 (est) | | CAS DataBase Reference | 52286-59-6(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 26-36 | | WGK Germany | 3 | | RTECS | LY9536700 | | HS Code | 29389090 |
| | Ginsenoside Re Usage And Synthesis |
| Chemical Properties | White solid | | Uses | Ginsenoside Re is an extract from ginger, responsible for some of the pharmacological functions. It displays cardiac contractility, anti-ischemic and anti-arrythmic activities. | | Definition | ChEBI: Ginsenoside Re is a ginsenoside found in Panax ginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an anti-inflammatory agent, an antineoplastic agent and a nephroprotective agent. It is a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a beta-D-glucoside, a ginsenoside, a tetracyclic triterpenoid, a disaccharide derivative and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | | in vivo | Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes and high-fat diet (HFD) rats through inhibition of JNK and NF-κB activation[2]. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of 20 mg/kg is lethal to mice, and 70% to 80% of the mice die within 60 h. However, pretreatment of the mice with Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent manner. With the doses of Rg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) or from 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg are protected from death compared to 80% survival of mice treated with an equal dose of Ginsenoside Re. To protect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential of Rg1 and Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats and then challenged the animals with LPS. The injection procedure itself causes a transient stress-induced increase in body temperature of ~1.2°C in each group. Thereafter, LPS-challenged rats without pretreatment develope a robust biphasic fever, with the first peak reaching ~1.5°C at 2 h and the second peak reaching 1.8°C at 4 h. In contrast, the temperature changes for the Rg1-, Ginsenoside Re-, and TAK-242-treated groups are only 0.9, 1.2, and 0.8°C at 2 h and 1.3, 1.4, and 1.0°C at 4 h, respectively. Pretreatment with Rg1, Ginsenoside Re, or TAK-242 significantly attenuates LPS-induced alterations in body temperature[3]. | | target | AMPK | TLR | p38MAPK | HO-1 | TNF-α | Potassium Channel | NO | Calcium Channel | ERK | Akt | mTOR | CD4 | Calcium Channel | c-Src | NOS | | IC 50 | Aβ1-40; Aβ1-42; NF-κB; JNK |
| | Ginsenoside Re Preparation Products And Raw materials |
|